SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin recalling anti-bacterial drug Ceftriaxone from US

21 Jan 2019 Evaluate

Lupin is voluntarily recalling 55,000 vials and 1,60,241 boxes of anti-bacterial drug Ceftriaxone for injection in various strengths. The recall has been initiated by Lupin Pharmaceuticals, Inc, a subsidiary of the company. The products have been manufactured at the company's facility in Mandideep in the state of Madhya Pradesh.

The company is recalling specific lots of drugs due to the presence of shredded rubber particulate matter from the stopper observed in reconstituted vials. The ongoing voluntary nationwide recall has been classified as Class-I. Such recalls are for dangerous or defective products that predictably could cause serious health problems.

Lupin Pharmaceuticals is also recalling 2,87,784 bottles of Cefdinir for Oral Suspension, used to treat bacterial infections for CGMP (Current Good Manufacturing Practice) deviations. It is classified as a Class-II recall, which is initiated in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2277.80 -62.40 (-2.67%)
24-Apr-2026 12:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.00
Dr. Reddys Lab 1345.00
Cipla 1300.00
Zydus Lifesciences 931.05
Lupin 2277.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×